- Home
- PKBK vs TNXP Comparison
PKBK vs TNXP Comparison
Compare PKBK & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKBK
- TNXP
- Stock Information
- Founded
- PKBK 1999
- TNXP 2007
- Country
- PKBK United States
- TNXP United States
- Employees
- PKBK 108
- TNXP N/A
- Industry
- PKBK Major Banks
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- PKBK Finance
- TNXP Health Care
- Exchange
- PKBK Nasdaq
- TNXP Nasdaq
- Market Cap
- PKBK 241.2M
- TNXP 272.0M
- IPO Year
- PKBK N/A
- TNXP N/A
- Fundamental
- Price
- PKBK $21.48
- TNXP $35.48
- Analyst Decision
- PKBK
- TNXP Strong Buy
- Analyst Count
- PKBK 0
- TNXP 2
- Target Price
- PKBK N/A
- TNXP $585.00
- AVG Volume (30 Days)
- PKBK 25.1K
- TNXP 729.5K
- Earning Date
- PKBK 07-18-2025
- TNXP 08-15-2025
- Dividend Yield
- PKBK 3.35%
- TNXP N/A
- EPS Growth
- PKBK 24.08
- TNXP N/A
- EPS
- PKBK 2.41
- TNXP N/A
- Revenue
- PKBK $64,206,999.00
- TNXP $10,041,000.00
- Revenue This Year
- PKBK N/A
- TNXP $11.66
- Revenue Next Year
- PKBK N/A
- TNXP $793.18
- P/E Ratio
- PKBK $8.93
- TNXP N/A
- Revenue Growth
- PKBK N/A
- TNXP N/A
- 52 Week Low
- PKBK $15.44
- TNXP $6.76
- 52 Week High
- PKBK $24.29
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- PKBK 71.48
- TNXP 52.96
- Support Level
- PKBK $20.37
- TNXP $33.71
- Resistance Level
- PKBK $20.92
- TNXP $38.13
- Average True Range (ATR)
- PKBK 0.49
- TNXP 2.62
- MACD
- PKBK 0.20
- TNXP -0.44
- Stochastic Oscillator
- PKBK 96.09
- TNXP 61.01
About PKBK Parke Bancorp Inc.
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.